3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Testicular Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms, Unknown Primary
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Death
1
Colonic Neoplasms
1
Interventions
Carboplatin
177
Radiotherapy
139
Cisplatin
110
Pemetrexed
102
Docetaxel
93
Paclitaxel
92
Gemcitabine
78
Erlotinib Hydrochloride
73
Magnetic Resonance Spectroscopy
72
Radiosurgery
67
Bevacizumab
65
pembrolizumab
64
Etoposide
60
Blood Specimen Collection
60
durvalumab
53
Specimen Handling
48
Nivolumab
48
Surveys and Questionnaires
47
Drug Therapy
41
Standard of Care
35
Radiation
33
osimertinib
32
atezolizumab
32
Surgical Procedures, Operative
30
Topotecan
29
Irinotecan
29
Gefitinib
29
Educational Status
29
Early Intervention, Educational
29
Biopsy
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lung Neoplasms
×
erythromycin propionate-N-acetylcysteinate
×
Clear all
NCT02966509
2018-10-31
EPAC
Stanford University
Phase NA
Completed
213 enrolled
20 charts